Novo Nordisk says Sanofi insulin lags degludec in study
COPENHAGEN | Tue Oct 2, 2012 6:03am EDT
COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said its insulin degludec had shown 43 percent lower rates of night-time low blood sugar levels than glargine from rival drugmaker Sanofi.
Novo Nordisk said in a statement the data was presented on Tuesday at the Annual Meeting of the European Association for the Study of Diabetes (EASD).
The data had been collected in a two-year phase IIIa study, Novo Nordisk said.
http://www.reuters.com/article/2012/10/02/us-novonordisk-idUSBRE8910BL20121002?feedType=RSS&feedName=healthNews
